What is Amgen Inc (AMGN)?
Amgen Inc trades as AMGN on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-06.
Is AMGN in a Closelooknet index?
Yes — Amgen Inc is a constituent of HALO Growth 100, as of 2026-11-06.
What is Amgen Inc's Closelooknet composite score?
56 out of 100, with momentum 88, quality 85 and valuation 34 sub-scores, as of 2026-11-06. Scores are Closelooknet's own research readings, not ratings or investment advice.
Where does AMGN trade against its moving averages?
Amgen Inc trades 13.5% above its 50-day and 27.1% above its 200-day moving average (8.6% above its 20-day). As of 2026-11-04 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.
How is AMGN doing against its Closelooknet index?
Over the past month Amgen Inc is +11.4% against +0.4% for the HALO Growth 100 — 11.0 points ahead of its index, as of 2026-11-05. Its Longevity & Healthspan sleeve is +2.7% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.
How does Amgen Inc compare with its peers?
Against its peer group (HALO Growth 100 · Longevity & Healthspan), Amgen Inc (AMGN) sits 0.8% below its 52-week high, 13.5% above its 50-day average; Regeneron Pharmaceuticals Inc (REGN) is 6.2% below, Vertex Pharmaceuticals Inc (VRTX) is 3.5% below, Zealand Pharma A/S (ZEAL.CO) is 57.4% below, as of 2026-11-04. Put any of them next to AMGN in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.
How does Amgen Inc trade when bond yields rise?
Over the past year Amgen Inc had a beta of 0.58 to TLT, the long-dated Treasury fund — it tends to move with bonds, higher than 53% of US names. On the 10 sessions in which long bonds fell most it moved −0.86% on average, against −0.74% for the S&P 500. As of 2026-11-05; The "How it trades on rate days" block on this page carries the lines.
What does Amgen Inc do?
Amgen discovers, develops and manufactures human therapeutics, with products spanning rheumatoid arthritis, osteoporosis, cardiovascular risk reduction and rare diseases such as Enbrel, Prolia and Repatha. It sells through pharmaceutical wholesale distributors to hospitals, clinics and pharmacies worldwide. It is headquartered in Thousand Oaks, California. Closelooknet's peer group places it with Eli Lilly, Regeneron, Zealand Pharma, Vertex, Illumina, Novo Nordisk, Natera and Gerresheimer, on the reasoning that demographics drives demand across the group; the market also compares it with Pfizer. (Company snapshot of 2026-09-17.)
Where does Amgen Inc sit in the AI build-out?
Amgen sits in our HALO Growth 100 index, in the Longevity & Healthspan sleeve, which groups GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders. Within that sleeve it functions as a broad-portfolio compounder, supplying chronic-disease treatments to a demand curve set by an ageing population rather than a single therapeutic bet. Amgen holds a seat in our HALO Growth 100, and also sits in the Nasdaq-100 and the Dow Jones Industrial Average. It carries a Closelooknet score, strongest on the quality module and weakest on valuation. The Morning 10 has quoted it once, noting a sharp single-day drop during a broader Wall Street sell-off. (Company snapshot of 2026-09-17.)
Does Amgen Inc pay a dividend?
Amgen Inc has paid 9.94 USD per share over the last twelve months, paid quarterly, a trailing yield of 2.16% on the 2026-11-05 close; the last distribution recorded in the price series was 2.52 USD on 2026-08-21. In fiscal 2025 the company paid 5.12 bn USD in dividends, 63% of that year’s free cash flow. The share count rose 0.2% over the fiscal year. As of 2026-11-05; the "Dividends and capital return" block on this page carries the lines.
What has Wall Street done on Amgen Inc recently?
The most recent analyst action on Amgen Inc on the Closelooknet wire is a price target by Cantor Fitzgerald on 2026-11-04 (target 465). 15 actions on the analyst wire since 2026-08-13: 15 target changes. Its latest earnings print on the wire, 2026-11-03: EPS 6.45 against 5.79 expected — a +11.4% beat. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.
What does this page show?
A live price chart with SMA overlays and drawing tools for AMGN, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.